- Home
- BIIB vs HOLX Comparison
BIIB vs HOLX Comparison
Compare BIIB & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- HOLX
- Stock Information
- Founded
- BIIB 1978
- HOLX 1985
- Country
- BIIB United States
- HOLX United States
- Employees
- BIIB N/A
- HOLX N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- HOLX Medical Electronics
- Sector
- BIIB Health Care
- HOLX Health Care
- Exchange
- BIIB Nasdaq
- HOLX Nasdaq
- Market Cap
- BIIB 19.9B
- HOLX 16.3B
- IPO Year
- BIIB 1991
- HOLX 1990
- Fundamental
- Price
- BIIB $125.59
- HOLX $56.51
- Analyst Decision
- BIIB Buy
- HOLX Hold
- Analyst Count
- BIIB 27
- HOLX 13
- Target Price
- BIIB $201.26
- HOLX $76.27
- AVG Volume (30 Days)
- BIIB 1.6M
- HOLX 3.4M
- Earning Date
- BIIB 05-01-2025
- HOLX 05-01-2025
- Dividend Yield
- BIIB N/A
- HOLX N/A
- EPS Growth
- BIIB 26.39
- HOLX 25.36
- EPS
- BIIB 10.12
- HOLX 2.39
- Revenue
- BIIB $9,816,400,000.00
- HOLX $4,026,500,000.00
- Revenue This Year
- BIIB N/A
- HOLX $3.14
- Revenue Next Year
- BIIB N/A
- HOLX $5.15
- P/E Ratio
- BIIB $12.43
- HOLX $23.76
- Revenue Growth
- BIIB 1.59
- HOLX 1.66
- 52 Week Low
- BIIB $110.04
- HOLX $51.90
- 52 Week High
- BIIB $238.00
- HOLX $84.67
- Technical
- Relative Strength Index (RSI)
- BIIB 55.21
- HOLX 43.87
- Support Level
- BIIB $119.18
- HOLX $54.84
- Resistance Level
- BIIB $124.82
- HOLX $59.02
- Average True Range (ATR)
- BIIB 3.81
- HOLX 1.62
- MACD
- BIIB 1.21
- HOLX 0.16
- Stochastic Oscillator
- BIIB 98.29
- HOLX 53.09
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.